위례의료복합피에프브이

비상장계속사업자

Wirye medical complex PFV co.,LTD

이창열

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

위례의료복합피에프브이

Business Reg. No. 7468802193 · CEO 이창열

I.Investment Overview

Target위례의료복합피에프브이 (7468802193)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명위례의료복합피에프브이
영문명Wirye medical complex PFV co.,LTD
대표자이창열
사업자등록번호7468802193
법인등록번호1101117959484
설립일2021.07.15

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW02024
영업이익100M KRW-7.42021-19.42022-337.82023-27.92024
순이익100M KRW-13.12021-60.82022-413.72023-1.82024
Item2024202320222021
자산총계4억원1,690.4억원1,544.2억원442.3억원
부채총계443.7억원2,128.3억원1,568.3억원405.6억원
자본총계-439.7억원-437.9억원-24.2억원36.7억원
매출액0원
영업이익-27.9억원-337.8억원-19.4억원-7.4억원
순이익-1.8억원-413.7억원-60.8억원-13.1억원

VI.Financial Ratios

FY2024 basis

영업이익률

순이익률

-45.46%

ROA

ROE

부채비율

자기자본비율

VII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

위례의료복합피에프브이 투심보고서 | Alpha Lenz